The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.
暂无分享,去创建一个
D. Bigner | H. Friedman | M. Bacolod | H S Friedman | D D Bigner | M. Colvin | M Colvin | S P Johnson | M D Bacolod | S M Lin | N S Bullock | N. Bullock | S. P. Johnson | S. M. Lin | S. M. Lin | S. M. Lin
[1] F. Kokocinski,et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.
[2] H. K. Kim,et al. Gene expression signatures associated with the resistance to imatinib , 2006, Leukemia.
[3] Robert Tampé,et al. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. , 2004, Physiology.
[4] Z. Duan,et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] C. Fenselau,et al. A biologically active metabolite of cyclophosphamide. , 1973, Cancer research.
[6] M. P. Gamcsik,et al. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity? , 2002, Cancer treatment and research.
[7] Guoyao Wu,et al. Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.
[8] D. Bigner,et al. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and-resistant medulloblastoma cell lines , 1995, Cancer Chemotherapy and Pharmacology.
[9] N. Sládek. Metabolism of oxazaphosphorines. , 1988, Pharmacology & therapeutics.
[10] D. Owen,et al. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. , 2005, The Journal of clinical investigation.
[11] Lakshmaiah Sreerama,et al. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study , 2002, Cancer Chemotherapy and Pharmacology.
[12] Yao-Tseng Chen,et al. CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.
[13] O. M. Friedman,et al. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. , 1977, Cancer research.
[14] Je-Jung Lee,et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.
[15] M. Volm,et al. O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts , 1998, International journal of cancer.
[16] J. Trojanowski,et al. Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med , 1985, Journal of neuropathology and experimental neurology.
[17] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[18] Jeffrey C. Allen,et al. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified phase II trial , 1983, Cancer.
[19] M. Makuuchi,et al. Expression of the MAGE gene family in human hepatocellular carcinoma , 1999, Cancer.
[20] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[21] V. Speirs,et al. Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. , 2007, International journal of oncology.
[22] D. Bigner,et al. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. , 2002, Molecular cancer therapeutics.
[23] M. Dolan,et al. Modulation of cyclophosphamide activity by O 6-alkylguanine-DNA alkyltransferase , 1999, Cancer Chemotherapy and Pharmacology.
[24] K. Uzawa,et al. Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. , 2007, International journal of oncology.
[25] A. Pegg,et al. The role of human O(6)-alkylguanine-DNA alkyltransferase in promoting 1,2-dibromoethane-induced genotoxicity in Escherichia coli. , 2000, Mutation research.
[26] J. Hilton,et al. Pharmacology of cyclophosphamide and metabolites. , 1981, Cancer treatment reports.
[27] B. Têtu,et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. , 2006, International journal of oncology.
[28] A. Pegg. Properties of mammalian O6-alkylguanine-DNA transferases. , 1990, Mutation research.
[29] X. Wu,et al. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] Robert Wechsler-Reya,et al. BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.
[31] T. Flynn,et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. , 2003, The Biochemical journal.
[32] R. Tampé,et al. Function of the transport complex TAP in cellular immune recognition. , 1999, Biochimica et biophysica acta.
[33] A. Monks,et al. Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells , 2002, British Journal of Cancer.
[34] L. Helson,et al. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. , 1981, Journal of neurosurgery.
[35] H. Friedman,et al. Cyclophosphamide resistance in medulloblastoma. , 1992, Cancer research.
[36] Jason E. Stewart,et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.
[37] Yana Zhang,et al. Cancer‐testis antigens in haematological malignancies , 2007, British journal of haematology.
[38] Stephen B. Howell,et al. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells , 2006, Cancer Chemotherapy and Pharmacology.
[39] K. Früh,et al. Antigen presentation by MHC class I and its regulation by interferon gamma. , 1999, Current opinion in immunology.
[40] E. D. de Vries,et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation , 2004, British Journal of Cancer.
[41] H. Friedman,et al. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. , 2002, Cancer treatment and research.
[42] C. Fenselau,et al. Alkylating properties of phosphoramide mustard. , 1976, Cancer research.
[43] U. Boehm,et al. Cellular responses to interferon-gamma. , 1997, Annual review of immunology.
[44] N. Sládek. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. , 1999, Current pharmaceutical design.
[45] Ingrid Lönnstedt. Replicated microarray data , 2001 .
[46] J. Trojanowski,et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. , 1988, The American journal of pathology.
[47] P. McHugh,et al. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. , 2001, The Lancet. Oncology.
[48] M. Dolan,et al. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. , 2004, Molecular cancer therapeutics.
[49] Yusuke Nakamura,et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. , 2003, Cancer research.
[50] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[51] P. Cresswell,et al. Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.
[52] J. Bakke,et al. Metabolism of cyclophosphamide by sheep. , 1972, Journal of agricultural and food chemistry.
[53] N. Sládek,et al. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. , 1993, Biochemical pharmacology.
[54] Laura Smith,et al. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model , 2007, Acta oncologica.
[55] S. Shammah,et al. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. , 1996, Blood.
[56] D. Schadendorf,et al. Enhanced expression of human ABC‐transporter tap is associated with cellular resistance to mitoxantrone , 2001, FEBS letters.
[57] Miki Ohira,et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. , 2005, Cancer research.
[58] A. Pifferi,et al. The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups. , 1998, European journal of cancer.
[59] Shufeng Zhou,et al. Metabolism and Transport of Oxazaphosphorines and the Clinical Implications , 2005, Drug metabolism reviews.
[60] T. A. Connors,et al. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. , 1974, Biochemical pharmacology.
[61] T. Witham,et al. l-Buthionine Sulfoximine Potentiates the Antitumor Effect of 4-Hydroperoxycyclophosphamide When Administered Locally in a Rat Glioma Model , 2001, Neurosurgery.
[62] C. Shimizu,et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.